The 1A1-K21-M22 monoclonal antibody specifically binds to CD267 which is also known as TACI (Transmembrane Activator and CAML Interactor). CD267 is a member of the of the Tumor Necrosis Factor Receptor (TNFR) Superfamily and is encoded by the TNFRSF13B gene. This 32 kDa type III transmembrane protein receptor binds to the ligands, BAFF (TNFSF13B/BLyS/CD257) and APRIL (TNFSF13/CD256). Ligand-bound CD267 transduces signals leading to the activation of transcription factors including NFAT, AP1, and NF-kappa-B. CD267 is expressed most notably on maturing subsets of B cells and myeloma cells. In CD267 deficient mice, B cell numbers are increased and mice develop autoimmune disorders suggesting that CD267 plays an important role in the regulation of B cell homeostasis.
The antibody was conjugated to an oligonucleotide that contains an antibody clone-specific barcode (ABC) flanked by a poly-A tail on the 3' end and a PCR handle (PCR primer binding site) on the 5' end. The ABC for this antibody was designed to be used with other BD AbSeq oligonucleotides conjugated to other antibodies. All AbSeq ABC sequences were selected in silico to be unique from human and mouse genomes, have low predicted secondary structure, and have high Hamming distance within the BD AbSeq portfolio, to allow for sequencing error correction and unique mapping. The poly-A tail of the oligonucleotide allows the ABC to be captured by the BD Rhapsody™ system. The 5' PCR handle allows for efficient sequencing library generation for Illumina sequencing platforms.
NOTE: The BD Rhapsody Single-Cell Analysis System must be used with the BD Rhapsody Express Instrument.